Pharmacological Properties of Salmeterol

NCT02558088 — Phase 4, Completed, 11 participants, University of Copenhagen

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Pharmacological Properties of Inhaled Salmeterol in Healthy Trained Males

Registry	NCT02558088
Status	Completed
Phase	Phase 4
Study type	Interventional; na, single group, masking: none, basic science
Enrollment	11 (Actual)
Sponsor	University of Copenhagen (Other)
Conditions	Pharmacokinetics in Healthy Young Men
Interventions	Salmeterol (Drug)
Dates	start 2014-09-01, primary completion 2016-07-01, completion 2016-07-01, first posted 2015-09-23, last updated 2017-01-31
Locations	1 site in Denmark

-Summary

The objective of the study is to help establish a urinary threshold for salmeterol on the World Anti-doping Agency prohibited list, to avoid supratherapeutic of this substance in competitive sports.

Hence, there is no hypothesis as such.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
salmeterol	Experimental	Drug: Salmeterol

Salmeterol (Drug)

+Outcome measures

Primary outcomes

Urine concentration of salmeterol [0-24 hours after administration of the study drug]

+Eligibility

Sex: Male, ages: 18 Years to 45 Years, accepts healthy volunteers

Inclusion Criteria:

* Male
* 18-45 years
* Healthy

Exclusion Criteria:

* Chronic disease
* Smoking
* Habitual use of medicine
* Allergy towards salmeterol
* Unable to exercise on a bike ergometer

+Locations (1)

Facility	City	Country	Status
Bispebjerg Hospital	Copenhagen, Select State	Denmark

+Investigators

Vibeke Backer, Professor, Principal investigator, Bispebjerg Hospital